Hepatocellular Carcinoma

Merck Announces KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib

Retrieved on: 
Monday, September 27, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, KEYNOTE-394, Hepatocellular Carcinoma, KEYTRUDA® (pembrolizumab) Injection, 100 mg, Merck, KEYNOTE-394, HEPATOCELLULAR CARCINOMA, KEYTRUDA® (PEMBROLIZUMAB) INJECTION, 100 MG, MERCK

Hepatocellular carcinoma, which is often diagnosed at an advanced stage, has a five-year survival rate of less than 15%.

Key Points: 
  • Hepatocellular carcinoma, which is often diagnosed at an advanced stage, has a five-year survival rate of less than 15%.
  • KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
  • KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
  • KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma.

China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma

Retrieved on: 
Wednesday, June 23, 2021
Oncology, Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Cancer, Clinical medicine, Medicine, Health effects of tobacco, Lung cancer, Cancer treatments, Oncology, Infectious causes of cancer, Head and neck cancer, Chemotherapy, Non-small-cell lung carcinoma, Esophageal cancer, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma, Tislelizumab, the Tislelizumab Clinical Program, BeiGene, NON-SMALL CELL LUNG CANCER, HEPATOCELLULAR CARCINOMA, TISLELIZUMAB, THE TISLELIZUMAB CLINICAL PROGRAM, BEIGENE

The pivotal clinical program of tislelizumab has seen tremendous progress lately, including two positive Phase 3 trials, one in esophageal cancer and the other in nasopharyngeal cancer.

Key Points: 
  • The pivotal clinical program of tislelizumab has seen tremendous progress lately, including two positive Phase 3 trials, one in esophageal cancer and the other in nasopharyngeal cancer.
  • NSCLC comprises the most common form of lung cancer, although diagnoses are usually delayed with most patients diagnosed at advanced stage.
  • A total of 334 patients in China were enrolled in the trial, randomized 2:1 to either the tislelizumab and chemotherapy arm or the chemotherapy arm.
  • Available at https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-she... ; accessed March 2021.
    iii U.S National Institute of Health (NIH) National Cancer Institute Surveillance, Epidemiology, and End Results Program (SEER) Cancer Stat Facts.

Merck and Eisai Receive Third Breakthrough Therapy Designation from FDA for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment

Retrieved on: 
Tuesday, July 23, 2019
Biotechnology, Pharmaceutical, Oncology, FDA, Health, Clinical trials, KEYNOTE-524/Study 116, Hepatocellular Carcinoma, LENVIMA® (lenvatinib) Capsules, 10 mg and 4 mg, Eisai

This is the third Breakthrough Therapy designation for the KEYTRUDA plus LENVIMA combination and is based on updated interim results from the Phase 1b trial KEYNOTE-524/Study 116.

Key Points: 
  • This is the third Breakthrough Therapy designation for the KEYTRUDA plus LENVIMA combination and is based on updated interim results from the Phase 1b trial KEYNOTE-524/Study 116.
  • When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA should be administered prior to chemotherapy when given on the same day.
  • When administering KEYTRUDA in combination with chemotherapy, administer KEYTRUDA prior to chemotherapy when given on the same day.
  • Under the agreement, the companies will jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with Mercks anti-PD-1 therapy KEYTRUDA.